As transcatheter aortic valve implantation (TAVI) moves beyond its 20-year milestone, two pioneers of the treatment—Alain Cribier (University Hospital of Rouen, Rouen, France) and Michael Reardon (Academic Institute Methodist DeBakey Heart & Vascular Center, Houston, USA)—reflect on its wide-reaching impact on the treatment of aortic disease.
Cribier turns the clock back to the first human implant of a TAVI valve in 2002, a moment in which he made history in the interventional treatment of valvular heart disease. Reardon tells Cardiovascular News about some of the key studies to have shaped the TAVI field, and looks to the future of transcatheter treatment.
